secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001193125-26-044616
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Therapeutics PAO Edmund Dunn to retire; Matthew Bowen appointed successor
--------------------------------------------------------------------------------

- Edmund Dunn, SVP, Corporate Controller and PAO, to retire effective April 3, 2026; no severance or disagreement.
- Matthew Bowen, age 37, promoted from Director, Finance to Corporate Controller and PAO effective April 3, 2026.
- Bowen joined Monte Rosa in June 2021 post-IPO; previously 7 years at Ernst & Young in audit.
- Bowen holds BS and MS in Accounting from Bryant University and is a licensed CPA in Massachusetts.
- No family relationships or related party transactions with Bowen; no arrangements for promotion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526044616/0001193125-26-044616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526044616/glue-20260209.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-044616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer